Ad
related to: fda indications for modafinil 50 25Ranked at No. 20 on the 2020 Disruptor 50 list. - CNBC
Search results
Results from the WOW.Com Content Network
Modafinil performs moderately (but better than armodafinil or solriamfetol) [30] as a drug to overcome excessive daytime sleepiness caused by obstructive sleep apnea, [31] though it is recommended that people with apnea use continuous positive airway pressure (CPAP) therapy, that is a sleep breathing apparatus to prevent apnea, before starting ...
Modafinil is a drug that helps keep people awake and alert (wakefulness-promoting agent or "eugeroic"). [ 1 ] [ 2 ] Most of the listed modafinil analogues are drugs that specifically target dopamine reuptake (reabsorption of a neurotransmitter by a neurotransmitter transporter ) with stronger effects ( selective DRIs with improved potency ...
A Cephalon-founded study in which patients were administered modafinil, methylphenidate, and a placebo found that modafinil produces "psychoactive and euphoric effects and feelings consistent with [methylphenidate]." [12] Like modafinil, armodafinil is an inhibitor and/or inducer of certain cytochrome P450 enzymes.
For premium support please call: 800-290-4726 more ways to reach us
The pharmaceutical company Cephalon, the original United States market rights holder of modafinil, has demonstrated initiative in the development of a successor to the prototypical eugeroic. [25] Of the more than twenty compounds preclinically tested in Cephalon's three-part drug discovery series, the compound fluorenol was selected as a lead. [26]
Solriamfetol is used to promote wakefulness in the treatment of excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea in adults. [1] It appears to be more effective in improving excessive daytime sleepiness associated with obstructive sleep apnea than certain other wakefulness-promoting agents including modafinil, armodafinil, and pitolisant.
The drug or other substance has a currently accepted medical use in treatment in the United States. Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule III. The complete list of Schedule IV substances is as follows.
Image source: The Motley Fool. Johnson & Johnson (NYSE: JNJ) Q4 2024 Earnings Call Jan 22, 2025, 8:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants